Bradykinin B(1) receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. The identification of non-peptide B(1) antagonists has been a notable advance in the kinin field that will allow evaluation of their therapeutic potential in the clinical realm. The current review is a high level summary of our contributions to the area that culminated in the discovery of a clinical candidate.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/156802608786264263 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!